J-Hope Scores At The Box Office, Earning A Top 10 Movie — After One Night
J-Hope's Hope on the Stage live viewing earns $4.1 million globally, breaking into the U.S. box ... More office top 10 for the May 30 to June 1 weekend. PARIS, FRANCE - JANUARY 20: J-Hope of BTS is seen outside Dior, during the Paris Fashion Week - Menswear Fall Winter 2023 2024 : Day Four on January 20, 2023 in Paris, France. (Photo by)
J-Hope has spent 2025 releasing solo smash after solo smash, with only short breaks in between his drops. He has scored several new Hot 100 hits in just the past few months, and he has a new tune coming soon — one that will likely become a charting success as well.
The BTS singer and rapper hasn't limited himself to streaming platforms and digital download storefronts when looking for commercial success. The South Korean musician recently appeared in cinemas around the world with a one-night-only event — one that helped him secure one of the top theatrical wins at the box office.
The BTS superstar recently released his film J-Hope Tour: 'Hope on the Stage' in Japan - Live Viewing. The one-night-only event brought fans of the singer-songwriter and rapper together in theaters around the globe to watch live as he performed from Osaka during one of the final dates of his solo trek, the Hope on the Stage Tour.
Despite the fact that the live viewing took place during just one evening, it still managed to bring in an impressive sum at the box office and stand out as a top performer.
According to Box Office Mojo, J-Hope's film earned just under $940,000 at the box office in the U.S. alone. That figure is enough for the movie to land at No. 10 on the list of the highest-grossing films in America during the weekend of May 30 through June 1.
When looking globally, the live viewing brought in just over $4.1 million. More than three-quarters of that figure coming from territories outside the U.S.
J-Hope claims the third loftiest debut on the ranking of the top-grossing films in America during that weekend. He lands behind new arrivals Karate Kid: Legends and Bring Her Back, which brought in $20.3 million and $7 million, respectively.
The weekend's grosses were still dominated by the live-action remake of Lilo & Stitch, which led the charge for a second consecutive frame with nearly $62 million. The last installment of the Mission: Impossible franchise holds steady at No. 2 with $27.2 million.
A top-grossing film is just another feather in J-Hope's cap, proving that 2025 is a huge year for him. He has already accrued three Hot 100 hits, upping his career total considerably with "LV Bag" alongside Don Toliver, Speedy, and Pharrell Williams, "Sweet Dreams" with Miguel and his own "Mona Lisa" — all of which spent time on the tally.
Later in June, he will drop "Killing It Girl" featuring rapper GloRilla, which will almost certainly become a hit across a variety of Billboard rankings, especially those focused on hip-hop.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Business Wire
an hour ago
- Business Wire
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. 'This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,' said Perry Sternberg, Chief Executive Officer of Sydnexis. 'This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.' The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. 'The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,' said Patrick Johnson, Ph.D., President of Sydnexis. 'This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.' Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. 'As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,' said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. 'The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.' About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.
Newsweek
2 hours ago
- Newsweek
The Good Life: The Closet of Our Dreams Actually Belongs to Sarah Jessica Parker
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Closet of Our Dreams Actually Belongs to SJP Manolo Blahniks, low-rise skirts, the Dior newspaper dress. Carrie Bradshaw's closet never goes out of style and it also hasn't left the hands, or the hangers, of Sarah Jessica Parker. SJP actually owns Carrie's entire closet, it's written into her contract (*screams in Carrie*). That's how the And Just Like That team is able to fill her closet with all the iconic pieces we know and love. "Well I have all of it, I've kept her archive since the very beginning. I have all of Carrie's outfits since the pilot," Parker said in a recent interview with Wonderland Magazine. "So I don't need to steal anything, cause I have it all!" Season 3 of AJLT is finally out and before we get into the goods, what did you think about that "cloud" hat? It's all over social and if you've been with the show for a while, it probably wasn't a huge surprise. Parker chose it herself and hoped that executive producer Michael Patrick King would be on board with the idea. "I've learned over the years that sometimes logic is not as good as a hat. It makes people say, 'I love it. I hate it. Oh, my God, what was she thinking?' King told USA Today. This season, SJP said her favorite pieces were found from London, including flea markets, vintage shops and private closets. "Tons of like turn of the century stuff and Victorian-era stuff and that stuff is incredible," Parker told Wonderland. Her fashion is impeccable as always, but what's going on in Carrie's life this season? Here's one take from my colleague, Lydia Patrick. Sarah Jessica Parker on the set of the "Sex And The City" reboot television film series, "And Just Like That" on October 22, 2024, NYC. Respondants to a YouGov Poll believe that Parker's character Carrie... Sarah Jessica Parker on the set of the "Sex And The City" reboot television film series, "And Just Like That" on October 22, 2024, NYC. Respondants to a YouGov Poll believe that Parker's character Carrie Bradshaw, would vote for Kamala Harris in the 2024 election. More zz/XNY/STAR MAX/IPx/STRMX, Associated Press By Lydia Patrick Love her or loathe her, Carrie Bradshaw knows how to make an entrance. Sarah Jessica Parker stutters back onto our screens for the latest series of And Just Like That... sporting a princess-like, nude sheer Simone Rocha dress, roses stuffed into her pockets, paired with a matching jacket, as she signs off a blank postcard to Aidan. Surprisingly, for a writer, she omits all words—just a heart scribbled at the bottom. Why? Because they have agreed to five years (yes, years!) of no-contact as Aidan resides in Virginia to raise his troubled son, who got into a drink-driving incident. This is very on-brand for the healthiest couple of all time, who reunited in season 2 of AJLT after a lifetime of emotional turbulence due to Carrie's infidelity and a called-off engagement in the original show Sex And The City. For them, "no contact" means exchanging blank post-cards, with a smattering of awkward phone sex. Who said romance was dead? Continue reading >>> Tap here to get this newsletter delivered to your inbox. iStock / Getty Images Plus Some of the biggest U.S. airlines are quietly charging solo travelers more than passengers who book as a pair, according to recent travel industry findings. American Airlines, Delta Air Lines and United Airlines have added new fare rules that in some cases require passengers to book at least two tickets to access the cheapest fares. That means solo travelers could end up paying as much as 70 percent more for the same flight. The rationale, according to airline analysts, is straightforward: solo travelers are more likely to be business travelers, who typically book flights with less concern about cost due to corporate budgets. Airlines are using fare rules to target those perceived as less price-sensitive. "It's just another way for airlines to continue segmenting their customers," Thrifty Traveler's Potter explained. Read more from Newsweek's Jesus Mesa. Miljan Živković/iStock / Getty Images Plus With dementia diagnoses on the rise as the U.S. population grows older, many people are wondering what they can do to protect their brain health. A new study points to a simple answer: your diet. Researchers found that sticking to the MIND diet—a hybrid of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets—were significantly less likely to develop Alzheimer's disease and related dementias. "Our study findings confirm that healthy dietary patterns in mid-to-late life and their improvement over time may prevent Alzheimer's and related dementias," said paper author professor Song-Yi Park of the University of Hawaii at Manoa. "This suggests that it is never too late to adopt a healthy diet to prevent dementia." Read more from Newsweek's Lucy Notarantonio. Four quick picks: Show your work ethic, with a tattoo? A tough day might soon show on your face, literally. Researchers have unveiled a wireless, temporary electronic forehead tattoo that tracks when your brain is working too hard. Read more. A tough day might soon show on your face, literally. Researchers have unveiled a wireless, temporary electronic forehead tattoo that tracks when your brain is working too hard. Read more. Late nights and depression: Are you a night owl? Researchers from the University of Surrey, England, revealed that mindfulness, sleep quality and alcohol consumption may link being a night owl with a greater risk of depression among young people. Read more. Are you a night owl? Researchers from the University of Surrey, England, revealed that mindfulness, sleep quality and alcohol consumption may link being a night owl with a greater risk of depression among young people. Read more. Tinder's new filter sparks debate: How much does height matter when it comes to dating? For some, it's a dealbreaker, and the dating app is testing a new height filter as summer kicks off. We're always listening to what matters most to our Tinder users—and testing the paid height preference is a great example of how we're building with urgency, clarity, and focus," a Tinder spokesperson told Newsweek. Read more. How much does height matter when it comes to dating? For some, it's a dealbreaker, and the dating app is testing a new height filter as summer kicks off. We're always listening to what matters most to our Tinder users—and testing the paid height preference is a great example of how we're building with urgency, clarity, and focus," a Tinder spokesperson told Newsweek. Read more. Majors with high unemployment: It's graduation season (congrats to my brother Josh!) and for college grads, that means it's time to look for a j-o-b. Some of the most popular majors, like computer science and physics, have high unemployment rates, data shows. See a list. This is a preview of The Good Life—Tap here to get this newsletter delivered straight to your inbox.
